CatenaBio is pioneering the next wave of antibody-drug conjugates (ADCs) for solid tumors - where existing mono-payload ADCs struggle with rapid tumor resistance and dose-limiting toxicities. Our proprietary CysTyr™ platform enables the precise conjugation of multiple payloads to a single antibody using a highly stable C–Y bond, delivering dual mechanisms of action that significantly boost efficacy, durability of response, and safety. Preclinical data show our lead asset CATB-101 achieves a multifold improvement in therapeutic index compared to leading ADCs, unlocking potential in high unmet-need indications like wt NSCLC, gastric, esophageal, H&N, and breast cancers (over $100B in aggregate market size). With an IND planned for Q1 2027, we are seeking Series A funding to propel clinical validation.

As investors and pharma leaders are racing to back ADC innovation - CatenaBio offers a unique, de-risked product-platform combination poised to lead the next wave of ADC innovation.